PennyPerformers.com: "Penny Stocks that Perform" picks are: AEMD, CADM, CICI, DSBO, VCRT

Jan 13, 2009 (M2 PRESSWIRE via COMTEX) -- VCRT | Quote | Chart | News | PowerRating -- Pennyperformers.com "Penny Stocks that Perform" picks are: Aethlon Medical, Inc. (OTCBB: AEMD), Cardima, Inc. (OTCBB: CADM), Communication Intelligence Corporation (OTCBB: CICI), Disaboom, Inc. (OTCBB: DSBO), Vicor Technologies, Inc. (OTCBB: VCRT)...and Proudly Introducing Proprietary Push Technology (PPT).

The Newest and Revolutionary Technology for Increasing Investor Visability.

REAL Awareness for REAL Companies.

Click below for a full demonstration.

http://newmediaadvisors.info/newmedia.swf

Sign-up for our FREE Stock Alerts AND NEWSLETTER at www.pennyperformers.com

Jan 13, 2009 -- Aethlon Medical, Inc. (OTCBB: AEMD | Quote | Chart | News | PowerRating) announced today that its Chief Science Officer, Dr. Richard H. Tullis will give a clinical presentation of the Aethlon Hemopurifier(R) at the 11th International Conference on Dialysis on January 29th. The presentation will review treatment outcomes of dialysis patients infected with Hepatitis-C (HCV), and will discuss the additional use of the Hemopurifier(R) in HIV and Cancer care. The conference will be held at Caesars Palace in Las Vegas, Nevada.

About Aethlon Medical

Aethlon Medical is the developer of the Hemopurifier(R), a first-in-class medical device designed to treat infectious disease. The Hemopurifier(R) provides real-time therapeutic filtration of infectious viruses and immunosuppressive particles, and is positioned to address the treatment of drug and vaccine resistant viruses. Additionally, the device holds promise in cancer care, as research studies have verified the Hemopurifier(R) is able to capture immunosuppressive particles secreted by tumors. The Hemopurifier(R) is designed to act both as a stand-alone therapeutic, and as an adjunct treatment to enhance clinical benefit of established therapies. Pre-clinical studies conducted by researchers representing leading government and non-government health organizations both in the United States and abroad have documented the effectiveness of the Hemopurifier(R) in capturing from circulation the viruses that constitute pandemic threats, including H5N1 Avian Influenza (bird flu), and Dengue Hemorrhagic Fever (DHF) from circulation. The company is conducting studies to support the use of the Hemopurifier(R) as a broad-spectrum treatment countermeasure against bioterror threats, including Smallpox, and Ebola, Marburg, and Lassa hemorrhagic fever. Regulatory and commercialization initiatives in the United States have been focused on bioterror threats, while international initiatives are directed toward naturally evolving pandemic threats, and chronic infectious disease conditions including the Human Immunodeficiency Virus (HIV) and Hepatitis-C (HCV). Aethlon has demonstrated safety of the Hemopurifier(R) in a 24-treatment human study at the Apollo Hospital in Delhi, India, and in an 18-treatment study at the Fortis Hospital, also located in Delhi. The company has also submitted an investigational device exemption (IDE) to the U.S. Food and Drug Administration (FDA) to advance the Hemopurifier(R) as a broad-spectrum treatment countermeasure against category "A" bioterror threats.

Jan 13, 2009 -- Cardima, Inc. (OTCBB: CADM | Quote | Chart | News | PowerRating) will showcase its products and technologies at the 45th Annual Meeting of the Society of Thoracic Surgeons (STS) conference January 26-28, 2009 in San Francisco and the 14th Annual International Boston Atrial Fibrillation Symposium January 15-17, 2009. Both conferences feature innovations in the treatment of atrial fibrillation.

At the STS conference, Cardima will sponsor a breakfast symposium, "Surgical Ablation - Keys to Success," highlighting the Company's Surgical Ablation System and featuring prominent physician speakers:

-- Li Poa, M.D., FACS, Chief of Cardiothoracic Surgery and Cardiac Surgery Program Director at Stamford Hospital and faculty member of Columbia University, who is among the world's leading authorities on surgical ablation for the treatment of atrial fibrillation (AF). Dr. Li Poa is head of the Cardima Center of Excellence and Training Program at Stamford Hospital. He has conducted extensive work perfecting thoracoscopic surgical techniques, and will train cardiothoracic surgeons in the use of the Cardima Surgical Ablation System.

-- Dr. Sanjeev Saksena, MD, FHRS, FACC, FESC FAHA, Clinical Professor of Medicine, Robert Wood Johnson School of Medicine and Medical Director of the Electrophysiology Research Foundation, has been the Director of the Cardiovascular Institute, Atlantic Health System (Eastern Campus) from 1999- 2004 and is a Past President of the North American Society of Pacing and Electrophysiology (NASPE). He is the Founding editor and current Editor-in- Chief of the Journal of Interventional Cardiac Electrophysiology that recently published an entire issue devoted to surgical ablation of atrial fibrillation in December 2007. He has been and is a Planning/Steering Committee member of the National Institute of Health AFFIRM & TOPCAT trials that have focused on atrial fibrillation.

The breakfast symposium will be held at the San Francisco Marriott beginning on January 27 at 6:00 a.m. For additional details, please contact Dilyana Hadjeva at dilyana.hadjeva@cardima.com. Cardima products and technology will be on display on the exhibition floor at booth #414 at the STS conference, which is being held at the Moscone West Convention Center.

"Our presence at STS and our symposium featuring two preeminent physicians in the field of AF provide an opportunity to showcase our Surgical Ablation System with many thought-leaders, both nationally and internationally, who attend this meeting," said Cardima's CEO, Robert Cheney. "We also look forward to using this venue to support the Surgical Ablation System's adoption by creating awareness of the Cardima Surgical Program and supporting the domestic and international Cardima distributors that are attending STS. Additionally, Cardima will be conducting a sales training program that is being held in conjunction with the conference."

Cardima will also showcase its PATHFINDER(R) products and technology for diagnosing arrhythmias to the electrophysiology community at exhibition booth #706 at the International Boston Atrial Fibrillation Symposium, which is being held at the Seaport Hotel & Conference Center, The World Trade Center in Boston. The company will also hold sales force training programs in conjunction with this conference.

About Cardima Surgical Ablation System

The Surgical Ablation System uses Cardima's patented technology for the ablation of cardiac tissue. The System incorporates a microcatheter-based surgical probe coupled with Cardima's INTELLITEMP(R), a radiofrequency energy management device. The probe incorporates irrigation, suction and illumination, which aid in placement and lesion depth. The Cardima Surgical Ablation System is able to create deep, long, linear and transmural cardiac lesions without gaps. The small, flexible design offers sole port-hole access, potentially decreasing procedure time, patient hospital stay and discomfort.

About Cardima PATHFINDER(R)

The Cardima PATHFINDER(R) and PATHFINDER(R) mini microcatheters allow entry into the most difficult and remote regions of the coronary vasculature. The small size, maneuverability, and flexibility differ from standard devices on the market.

About Atrial Fibrillation

Atrial fibrillation (AF) is the most common cardiac arrhythmia and a major concern for healthcare providers worldwide. AF symptoms typically include a rapid and irregular heartbeat, palpitations, discomfort and dizziness. During AF irregular, disorganized and quivering spasms of atrial tissue result in the heart's failure to pump adequate amounts of blood throughout the body. AF is a leading cause of stroke, can cause congestive heart failure and adds to the morbidity of any underlying heart disease. Recent estimates are that more than 2.5 million people in the U.S. have atrial fibrillation, of which 1 million are symptomatic yet do not respond well to drug therapy. The cause of AF is unknown and there is no variation by geography or ethnicity. The incidence of AF increases with age. Furthermore, about 200,000 new cases are diagnosed each year in the U.S.

About Cardima

Cardima, Inc. has developed the PATHFINDER(R), TRACER(TM) and REVELATION(R) Series of diagnostic catheters, the VUEPORT(R) and NAVIPORT(R) Series of guiding catheters, the INTELLITEMP(R) Energy Management Device and the Surgical Ablation System. All of these Cardima devices have received CE mark approval and U.S. Food and Drug Administration (FDA) 510(k) clearance. The REVELATION(R) Series of ablation catheters with the INTELLITEMP(R) EP Energy Management Device, developed for the treatment of atrial fibrillation (AF), has received CE mark approval and is marketed in Europe.

PATHFINDER(R), TRACER(TM), VUEPORT(R), NAVIPORT(R), REVELATION(R) and INTELLITEMP(R) are registered trademarks of Cardima, Inc.

Jan 13, 2009 -- Communication Intelligence Corporation ("CIC") (OTCBB: CICI), a leading supplier of electronic signature solutions for business process automation in the financial industry* and the recognized leader** in biometric signature verification announced today that two leading providers of property and casualty insurance for auto, home and business have deployed CIC's SignatureOne(R) Ceremony(R) Server Solution to provide a completely paperless process for their customers.

The SignatureOne Ceremony Server is a J2EE server product that provides the capability to define and manage an electronic signature process within a Service Oriented Architecture to be implemented in an On-Premise Deployed Model or through a Software as a Service (SaaS) environment. This product enables the use of web services to pass documents and/or packages of documents and related data to a server that facilitates end-to-end management of multi-party approvals of documents, truly enabling the straight through processing of electronic forms.

"We are pleased that two of the top-5 US insurers chose CIC to fulfill their automation needs," stated Guido DiGregorio, CIC's Chairman & CEO. "The cost and time savings of doing business online are significant. CIC's electronic signature technology provides these leading insurers the final and essential step to easily migrate to a truly paperless environment. With their focus on full functioning, easily extensible and proven electronic signature technology, CIC was the natural choice for these leading insurance companies because of our extensive and successful track record of deployment in the financial services sector. We look forward to continuing the contributions our electronic signature technology is affording the insurance industry in meeting the challenges and market demands the industry is facing including sales process automation and enabling truly straight through processing of electronic forms."

About CIC

Communication Intelligence Corporation ("CIC") is a leading supplier of electronic signature solutions for business process automation in the Financial Industry and the recognized leader in biometric signature verification. CIC's products enable companies to achieve truly paperless work flow in their eBusiness processes by enabling them with "The Power to Sign Online(R)" with multiple signature technologies across virtually all applications in SaaS and fully deployed delivery models.

Industry leaders such as AEGON, AIG, Charles Schwab, Prudential, Nationwide (UK), Snap-on Credit and Wells Fargo chose CIC's products to meet their needs. CIC has deployments with over 400 channel partners and enterprises worldwide representing hundreds of thousands of users, with over 500 million electronic signatures captured, eliminating the need for over a billion pieces of paper. CIC sells directly to enterprises and through system integrators, channel partners and OEMs. CIC is headquartered in Redwood Shores, California and has a joint venture, CICC, in Nanjing, China.

In December 2008, CIC was named to Forrester Research's "Hot Banking Tech Companies To Watch in 2009" Report.

In October 2007, CIC was awarded the 2007 Global Frost & Sullivan Award for Market Leadership in the dynamic signature verification market.

Jan 13, 2009 -- Disaboom, Inc. (OTCBB: DSBO), the leading online resource for people with disabilities, today announced the launch of its Inauguration 2009 initiative.

Disaboom and Disabled Politico - its internationally-recognized team of political bloggers -- will be on the ground in Washington during the Inauguration 2009 week to deliver live coverage from the Inaugural week's activities and events. While there, the team will be interviewing key individuals critical to the interests of the disability community.

"The Obama campaign contacted us last summer to post their disability platform on our site to reach out to people living with disabilities," notes Kim Dority, Vice President of Content for Disaboom. "It showed that they took disability issues seriously, and recognized the importance of this large and growing constituency. Being able to provide live coverage for both the Inauguration and the Disability Power and Pride Inaugural Ball brings this connection full circle for us."

In addition to Disabled Politico's live Inauguration 2009 coverage, Disaboom has also launched an Inauguration 2009 portal that brings together:

-- Barack Obama's profile and Disability Platform

-- Key issues coverage

-- Interviews with major political figures related to disability issues

-- Disaboom's Democratic National Convention coverage

-- Related Disabled Politico posts

-- Daily polls on key policy questions related to disability issues

"The Obama Disability Platform commits to changes that are critically important to the independence and well-being of the disability community. We're excited to be present at the inaugural events, and look forward to Disabled Politico's continuing coverage of these key issues," states Ms. Dority.

About Disaboom

Disaboom, Inc. was founded as a dynamic, diverse, and interactive online community dedicated to constantly improving the way people with disabilities or functional limitations live their lives. It also serves as a comprehensive online resource not only for people living with such conditions, but also for their immediate families and friends, caregivers, recreation and rehabilitation providers, and employers. More than 54 million American adults live with disabilities or functional limitations today in the United States alone. Founded and designed by doctors and fellow disaboomers to meet this community's specific needs, www.disaboom.com brings together content and tools, ranging from specialized health information to social networking to daily living resources, in a single interactive site.

Jan 13, 2009 -- Vicor Technologies, Inc. (OTCBB: VCRT | Quote | Chart | News | PowerRating) today announced that Chief Medical Officer Daniel N. Weiss, MD, FACC, was interviewed by EP Lab Digest about Vicor's PD2i algorithm and its approach to sudden cardiac death risk stratification. Vicor Technologies, Inc. (OTCBB: VCRT | Quote | Chart | News | PowerRating) is a development-stage biotechnology company focused on the commercialization of innovative non-invasive diagnostics using its patented, proprietary PD2i algorithm.

New Paradigm in Sudden Cardiac Death Risk Stratification: Interview with Daniel N. Weiss, MD, FACC appears in the January 2009 edition (http://www.eplabdigest.com/articles/New-Paradigm-Sudden-Cardiac-Death-Risk-Stratification). EP Lab Digest is published for physicians and lab professionals specializing in cardiology and electrophysiology.

In the interview, Dr. Weiss explains Vicor's patented, proprietary PD2i algorithm and how it was created. Additionally, he identifies Vicor's current applications for the PD2i -- the PD2i CA (Cardiac Analyzer) for sudden cardiac death (SCD) risk stratification and the PD2i VS (Vital Sign) for identifying those in need of immediate life-saving intervention -- and the status of clinical trials of and FDA 510(k) approval to market these applications.

"We are pleased to note the cardiology and electrophysiology community's growing interest in Vicor's clinically proven approach to identifying patients at risk of SCD, as reflected by the EP Lab Digest interview of Dr. Weiss," stated David H. Fater, Vicor President and Chief Executive Officer. "With more than 500,000 deaths annually, SCD is a leading cause of death in the U.S., yet there is currently no accurate method to identify those at risk of SCD. While approximately 12 million U.S. cardiac patients meet the criteria for being at elevated risk of SCD -- and are able to receive a preventive implantable cardioverter defibrillator (ICD) as a result -- studies reveal that 76% of ICDs never fire, suggesting a lack of true need in those patients with ICDs and resulting in unnecessary implantations with all the associated health risks and costs -- approximately $75,000 per person. Conversely, and perhaps more importantly, only 20 to 30% of those who've suffered SCD -- such as Tim Russert -- would have met the current criteria for an ICD, leaving 70 to 80% unprotected," concluded Mr. Fater.

About Vicor Technologies, Inc.

Vicor is a development-stage biotechnology company focused on the commercialization of innovative non-invasive diagnostics employing operational software and its patented, proprietary PD2i algorithm, a deterministic, non-linear analytic measure that accurately evaluates electrophysiological potentials with high sensitivity and high specificity to predict future pathological events in target populations.

Vicor currently has three products employing the PD2i algorithm. The PD2i Analyzer, which has received FDA 510(k) approval, measures heart rate variability. The PD2i VS (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. FDA 510(k) approval to market the PD2i VS is expected in 2009. The PD2i CA (Cardiac Analyzer), in a multi-site, multi-year trial (the VITAL Trial) being conducted by the Harvard Clinical Research Institute, identifies patients at risk of suffering sudden cardiac death. FDA 510(k) approval to market the PD2i CA is expected in early 2010.

Vicor anticipates developing additional applications using the PD2i to enable early detection and risk stratification for a variety of other disorders and diseases.

The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense or the U.S. Government of the information, products or services contained therein.

About PennyPerformers.com

PennyPerformers.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.

Penny Performers email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Penny Performers Report home page at www.PennyPerformers.com and select the "join now" button.

Join us at www.PennyPerformers.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. PennyPerformers.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyPerformers.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. PennyPerformers.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), PennyPerformers.com is owned and operated by PennyPerformers.com. Neither PennyPerformers.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since PennyPerformers.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in PennyPerformers.com statements and opinions and such statements and opinions cannot be considered independent. PennyPerformers.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. PennyPerformers.com services are often paid for using free-trading shares. PennyPerformers.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: www.PennyPerformers.com/disclaimer.htm

CONTACT: Pennyperformers.com e-mail: info@pennyperformers.com WWW: http://www.PennyPerformers.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index